TriangleAxatilimab (NCT06523556)
Axatilimab trial for Advanced Myeloproliferative Neoplasms, MDS/MPN and High-Risk CMML (NCT06523556). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with advanced myeloproliferative neoplasms, overlap syndromes with myelodysplastic syndrome, or high risk chronic myelomonocytic leukemia.
The idea: give axatilimab, an antibody given by vein that blocks a protein on certain white blood cells that may help the cancer grow. The first part tests axatilimab alone. The second part adds azacitidine, a standard chemotherapy.
The study looks for the best dose and how well it works.
This phase 1 and 2 study plans 49 patients. At Ohio State University Comprehensive Cancer Center in Columbus, Uma Borate leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.